| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NRRHEUM.2015.172 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/nrrheum.2015.172 |
| P932 | PMC publication ID | 5314913 |
| P698 | PubMed publication ID | 26698023 |
| P2093 | author name string | Andras Perl | |
| P2860 | cites work | Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice. | Q46619969 |
| Rapamycin prevents the development of nephritis in lupus-prone NZB/W F1 mice. | Q46643922 | ||
| PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus | Q46674138 | ||
| mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes | Q46823840 | ||
| Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study | Q46882806 | ||
| Treatment-related fatigue with everolimus and temsirolimus in patients with cancer-a meta-analysis of clinical trials | Q46909057 | ||
| Prevention of murine lupus disease in (NZBxNZW)F1 mice by sirolimus treatment. | Q46982107 | ||
| Proliferation signal inhibitors in the treatment of lupus nephritis: preliminary experience. | Q47361768 | ||
| Up-regulation of fatty acid oxidation in the ligament as a contributing factor of ankylosing spondylitis: A comparative proteomic study | Q47804730 | ||
| Inhibition of PI3Kδ reduces kidney infiltration by macrophages and ameliorates systemic lupus in the mouse. | Q50798715 | ||
| Enhanced phosphoinositide 3-kinase δ activity is a frequent event in systemic lupus erythematosus that confers resistance to activation-induced T cell death. | Q50997716 | ||
| The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin. | Q51547435 | ||
| Glutaminolysis activates Rag-mTORC1 signaling. | Q52301079 | ||
| Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. | Q35404457 | ||
| The PI3K/Akt/PTEN/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis? | Q35680138 | ||
| Oxidative stress and Treg depletion in lupus patients with anti-phospholipid syndrome | Q35732790 | ||
| Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis | Q35809286 | ||
| ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients | Q35842117 | ||
| ARG2 impairs endothelial autophagy through regulation of MTOR and PRKAA/AMPK signaling in advanced atherosclerosis | Q35852802 | ||
| Shared signaling networks active in B cells isolated from genetically distinct mouse models of lupus. | Q35879514 | ||
| Gpx4 ablation in adult mice results in a lethal phenotype accompanied by neuronal loss in brain | Q35925974 | ||
| Rheumatoid Arthritis, Anti-Cyclic Citrullinated Peptide Positivity, and Cardiovascular Disease Risk in the Women's Health Initiative | Q36001551 | ||
| Rictor/mTORC2 signaling mediates TGFβ1-induced fibroblast activation and kidney fibrosis | Q36022483 | ||
| Comprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycin | Q36024179 | ||
| N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial | Q36139749 | ||
| Evaluating oxidative stress in human cardiovascular disease: methodological aspects and considerations | Q36141348 | ||
| Increased survival and reduced renal injury in MRL/lpr mice treated with a novel sphingosine-1-phosphate receptor agonist | Q36461786 | ||
| GATA-3 regulates the homeostasis and activation of CD8+ T cells | Q36487600 | ||
| Metabolic stress controls mTORC1 lysosomal localization and dimerization by regulating the TTT-RUVBL1/2 complex. | Q36532572 | ||
| Therapeutic targets: MTOR and related pathways | Q36592032 | ||
| Matched and mismatched metabolic fuels in lymphocyte function | Q36640334 | ||
| Duration of rapamycin treatment has differential effects on metabolism in mice | Q36857264 | ||
| ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity | Q36979971 | ||
| The alliance of sphingosine-1-phosphate and its receptors in immunity | Q37010807 | ||
| Rapamycin ameliorates IgA nephropathy via cell cycle-dependent mechanisms | Q37071587 | ||
| Rab5 modulates aggregation and toxicity of mutant huntingtin through macroautophagy in cell and fly models of Huntington disease | Q37083085 | ||
| HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations | Q37123874 | ||
| Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor-beta | Q37129967 | ||
| mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function | Q37137541 | ||
| Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine | Q37209229 | ||
| A rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sjögren's syndrome | Q37228071 | ||
| AMPKα1 deficiency amplifies proinflammatory myeloid APC activity and CD40 signaling | Q37309942 | ||
| The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR. | Q37319760 | ||
| Signal transducer and activator of transcription 3 (STAT3) mediates amino acid inhibition of insulin signaling through serine 727 phosphorylation | Q37467580 | ||
| Normalization of CD4+ T cell metabolism reverses lupus | Q37625717 | ||
| CaMK4-dependent activation of AKT/mTOR and CREM-α underlies autoimmunity-associated Th17 imbalance | Q37726675 | ||
| Common toxicities of mammalian target of rapamycin inhibitors | Q37866137 | ||
| MicroRNA let-7i induced autophagy to protect T cell from apoptosis by targeting IGF1R. | Q53012346 | ||
| Cartilage-specific deletion of mTOR upregulates autophagy and protects mice from osteoarthritis. | Q53061352 | ||
| Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program. | Q54457299 | ||
| PI3K signalling: the path to discovery and understanding. | Q54527804 | ||
| TSC1 controls macrophage polarization to prevent inflammatory disease. | Q55071503 | ||
| Inhibition of the mTORC pathway in the antiphospholipid syndrome. | Q55072769 | ||
| Phase 2 enzyme induction by conjugated linoleic acid improves lupus-associated oxidative stress | Q57600352 | ||
| Conjugated linoleic acid enhances glutathione synthesis and attenuates pathological signs in MRL/MpJ-Faslprmice | Q57600355 | ||
| Hypoxia induces mitochondrial mutagenesis and dysfunction in inflammatory arthritis | Q59042062 | ||
| Rapamycin for immunosuppression in organ allografting. | Q64891783 | ||
| A double-blind, cross-over, study of oral N-acetylcysteine in Sjögren's syndrome | Q68157844 | ||
| Rapamycin in experimental renal allografts in dogs and pigs | Q68425887 | ||
| Differential expression of type I insulin-like growth factor receptors in different stages of human T cells | Q72209849 | ||
| Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus | Q72296666 | ||
| Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study | Q73106702 | ||
| Pathogenic T cells in murine lupus exhibit spontaneous signaling activity through phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways | Q73249101 | ||
| Effect of N-acetylcysteine on human diaphragm strength and fatigability | Q73885909 | ||
| Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin) | Q74593343 | ||
| Transforming growth factor-beta activation of phosphatidylinositol 3-kinase is independent of Smad2 and Smad3 and regulates fibroblast responses via p21-activated kinase-2 | Q81480914 | ||
| Treatment strategies for a rheumatoid arthritis patient with interstitial lung disease | Q82758303 | ||
| Association between T lymphocyte sub-sets apoptosis and peripheral blood mononuclear cells oxidative stress in systemic lupus erythematosus | Q83339044 | ||
| Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy | Q83584894 | ||
| Suppression of experimental arthritis through AMP-activated protein kinase activation and autophagy modulation | Q85487123 | ||
| Akt-dependent enhanced migratory capacity of Th17 cells from children with lupus nephritis | Q85844477 | ||
| Analysis of Programmed Death-1 in Patients with Psoriatic Arthritis | Q86695201 | ||
| A 50-Year-Old Woman With Cowden Syndrome and Joint Pains | Q87338307 | ||
| Effects of the immunosuppressant rapamycin on the expression of human α2(I) collagen and matrix metalloproteinase 1 genes in scleroderma dermal fibroblasts | Q87444274 | ||
| Systemic lupus erythematosus in a patient with PTEN hamartoma tumour syndrome | Q87465557 | ||
| Metformin downregulates Th17 cells differentiation and attenuates murine autoimmune arthritis | Q44895744 | ||
| Rapamycin unbalances the polarization of human macrophages to M1. | Q45057583 | ||
| In situ analysis of interleukin-23- and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis | Q45102170 | ||
| Modification of lupus-associated 60-kDa Ro protein with the lipid oxidation product 4-hydroxy-2-nonenal increases antigenicity and facilitates epitope spreading | Q45275275 | ||
| Efficacy of rapamycin in patient with juvenile rheumatoid arthritis | Q45282294 | ||
| Age-related CD8+ T cell clonal expansions express elevated levels of CD122 and CD127 and display defects in perceiving homeostatic signals | Q45861913 | ||
| Mortality and causes of death in systemic lupus erythematosus. | Q45986924 | ||
| Limited utility of rapamycin in severe, refractory Wegener's granulomatosis. | Q46243991 | ||
| IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade. | Q46314569 | ||
| Defective PTEN regulation contributes to B cell hyperresponsiveness in systemic lupus erythematosus | Q46405400 | ||
| Interleukin-17-induced proliferation of fibroblast-like synovial cells is mTOR dependent | Q46426683 | ||
| Aberrant expression of microRNAs in T cells from patients with ankylosing spondylitis contributes to the immunopathogenesis | Q46439316 | ||
| Sirolimus-eluting stent for in-stent restenosis of left main coronary artery in takayasu arteritis | Q46508696 | ||
| Rab5 and class III phosphoinositide 3-kinase Vps34 are involved in hepatitis C virus NS4B-induced autophagy. | Q35274953 | ||
| Deranged bioenergetics and defective redox capacity in T lymphocytes and neutrophils are related to cellular dysfunction and increased oxidative stress in patients with active systemic lupus erythematosus | Q35326330 | ||
| Autophagy and cartilage homeostasis mechanisms in joint health, aging and OA | Q35335855 | ||
| A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1 | Q24294219 | ||
| Human VPS34 and p150 are Rab7 Interacting Partners | Q24299781 | ||
| Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and control of RNA polymerase III-dependent transcription in cancer cells | Q24303535 | ||
| The p85alpha subunit of phosphatidylinositol 3'-kinase binds to and stimulates the GTPase activity of Rab proteins | Q24304389 | ||
| The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1 | Q24315566 | ||
| Inhibition of mTORC1 by astrin and stress granules prevents apoptosis in cancer cells | Q24318126 | ||
| AMPK phosphorylation of raptor mediates a metabolic checkpoint | Q24329244 | ||
| Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity | Q24598427 | ||
| Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism | Q24603034 | ||
| Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks | Q24612235 | ||
| Rapamycin fed late in life extends lifespan in genetically heterogeneous mice | Q24647805 | ||
| mTOR regulates memory CD8 T-cell differentiation | Q24648624 | ||
| Cellular and molecular mechanisms of fibrosis | Q24648892 | ||
| PKA: lessons learned after twenty years | Q26823926 | ||
| TSC2 mediates cellular energy response to control cell growth and survival | Q27860970 | ||
| All cyclophilins and FK506 binding proteins are, individually and collectively, dispensable for viability in Saccharomyces cerevisiae | Q27937279 | ||
| Ksp1 kinase regulates autophagy via the target of rapamycin complex 1 (TORC1) pathway | Q27937363 | ||
| mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging | Q28081442 | ||
| Regulation of translation initiation in eukaryotes: mechanisms and biological targets | Q28111696 | ||
| Differential regulation of distinct Vps34 complexes by AMPK in nutrient stress and autophagy | Q28115189 | ||
| Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle | Q28140704 | ||
| A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis | Q28183038 | ||
| Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus | Q28216909 | ||
| Dual mTOR Inhibition Is Required to Prevent TGF-β-Mediated Fibrosis: Implications for Scleroderma | Q28264437 | ||
| Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex | Q28273915 | ||
| ATP-competitive inhibitors of mTOR: an update. | Q37886209 | ||
| mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques | Q38188723 | ||
| PTEN. | Q38218236 | ||
| Current treatment strategies for inhibiting mTOR in cancer | Q38286529 | ||
| Association of impaired phosphatidylinositol 3-kinase activity in GLUT1-containing vesicles with malinsertion of glucose transporters into the plasma membrane of fibroblasts from a patient with severe insulin resistance and clinical features of Wern | Q38315071 | ||
| Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis | Q38323060 | ||
| mTOR: a pharmacologic target for autophagy regulation | Q38345168 | ||
| cAMP inhibits mammalian target of rapamycin complex-1 and -2 (mTORC1 and 2) by promoting complex dissociation and inhibiting mTOR kinase activity. | Q38657890 | ||
| Ceramide inhibits insulin-stimulated Akt phosphorylation through activation of Rheb/mTORC1/S6K signaling in skeletal muscle | Q39013537 | ||
| HRES-1/Rab4 promotes the formation of LC3(+) autophagosomes and the accumulation of mitochondria during autophagy | Q39036134 | ||
| Metabolism. Differential regulation of mTORC1 by leucine and glutamine | Q39211265 | ||
| mTOR binds to the promoters of RNA polymerase I- and III-transcribed genes | Q39758212 | ||
| Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction | Q40437839 | ||
| Disrupted RabGAP function of the p85 subunit of phosphatidylinositol 3-kinase results in cell transformation. | Q40446586 | ||
| Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue | Q40693029 | ||
| PI3K-C2γ is a Rab5 effector selectively controlling endosomal Akt2 activation downstream of insulin signalling | Q40810931 | ||
| Rapamycin: in vitro profile of a new immunosuppressive macrolide | Q40841533 | ||
| Human double-negative T cells in systemic lupus erythematosus provide help for IgG and are restricted by CD1c | Q40846574 | ||
| Leptin and Neutrophil-Activating Peptide 2 Promote Mesenchymal Stem Cell Senescence Through Activation of the Phosphatidylinositol 3-Kinase/Akt Pathway in Patients With Systemic Lupus Erythematosus | Q40923689 | ||
| PTENtiating autoimmunity through Treg cell deregulation | Q41234039 | ||
| Positive crosstalk between arginase-II and S6K1 in vascular endothelial inflammation and aging | Q41412735 | ||
| Regulation of autophagy and its associated cell death by "sphingolipid rheostat": reciprocal role of ceramide and sphingosine 1-phosphate in the mammalian target of rapamycin pathway | Q41463478 | ||
| Autophagy regulates endoplasmic reticulum homeostasis and calcium mobilization in T lymphocytes | Q41486560 | ||
| mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self-association and function through AMBRA1 and TRAF6. | Q41792378 | ||
| mTOR Signaling Cascade in Psoriatic Disease: Double Kinase mTOR Inhibitor a Novel Therapeutic Target | Q41858959 | ||
| Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus | Q41977234 | ||
| Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. | Q41983843 | ||
| Insulin-like growth factor induces phosphorylation of immunoreactive insulin receptor substrate and its association with phosphatidylinositol-3 kinase in human thymocytes | Q42013443 | ||
| Failed degradation of JunB contributes to overproduction of type I collagen and development of dermal fibrosis in patients with systemic sclerosis | Q42077845 | ||
| SIRT1 limits the function and fate of myeloid-derived suppressor cells in tumors by orchestrating HIF-1α-dependent glycolysis | Q42248309 | ||
| Loss of phosphatase and tensin homolog (PTEN) in myeloid cells controls inflammatory bone destruction by regulating the osteoclastogenic potential of myeloid cells. | Q42445667 | ||
| Mammalian target of rapamycin and its downstream signalling components are activated in psoriatic skin | Q42520536 | ||
| The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment | Q42593305 | ||
| Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors | Q42721039 | ||
| Deregulation of Rab5 and Rab4 proteins in p85R274A-expressing cells alters PDGFR trafficking | Q42825426 | ||
| Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis | Q43053141 | ||
| Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis | Q43053164 | ||
| Calcium/calmodulin-dependent protein kinase II (CaMKII) regulates tumour necrosis factor-related apoptosis inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells (FLS) by phosphorylation of Akt. | Q43165294 | ||
| PPARγ deficiency results in severe, accelerated osteoarthritis associated with aberrant mTOR signalling in the articular cartilage | Q43169841 | ||
| Sirolimus-eluting stent implantation for ostial stenosis of left main coronary artery after Bentall operation in aortitis syndrome | Q43178277 | ||
| Oxidative stress in systemic lupus erythematosus: relationship to Th1 cytokine and disease activity | Q43182787 | ||
| The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin | Q43199035 | ||
| CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages. | Q43583466 | ||
| Antioxidants suppress mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus (SLE). | Q43599866 | ||
| Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. | Q43956895 | ||
| Sirolimus lowers myeloperoxidase and p-ANCA titers in a pediatric patient before kidney transplantation | Q44082860 | ||
| PI3 kinase δ is a key regulator of synoviocyte function in rheumatoid arthritis | Q44088816 | ||
| Oxidative stress is involved in the heat stress-induced downregulation of TCR zeta chain expression and TCR/CD3-mediated [Ca(2+)](i) response in human T-lymphocytes | Q44118885 | ||
| The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial | Q44324616 | ||
| T cell receptor alpha/beta expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis | Q44381577 | ||
| Protective Effect of the Immunosuppressant Sirolimus Against Aortic Atherosclerosis In Apo E-Deficient Mice | Q44444364 | ||
| Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing | Q44535307 | ||
| Rab7 is required for the normal progression of the autophagic pathway in mammalian cells | Q44892471 | ||
| Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate | Q28280837 | ||
| High-dose acetylcysteine in idiopathic pulmonary fibrosis | Q28283438 | ||
| RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs | Q28286431 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Phosphofructokinase deficiency impairs ATP generation, autophagy, and redox balance in rheumatoid arthritis T cells | Q28298650 | ||
| Rapamycin (sirolimus) inhibits proliferating cell nuclear antigen expression and blocks cell cycle in the G1 phase in human keratinocyte stem cells | Q28378927 | ||
| Oligodendrocyte precursor cell-intrinsic effect of Rheb1 controls differentiation and mediates mTORC1-dependent myelination in brain | Q28508935 | ||
| Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility | Q29417082 | ||
| The 1982 revised criteria for the classification of systemic lupus erythematosus | Q29547225 | ||
| An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1 | Q29614563 | ||
| Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus | Q29614922 | ||
| Activation of a metabolic gene regulatory network downstream of mTOR complex 1 | Q29615179 | ||
| mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase | Q29616153 | ||
| The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? | Q29618125 | ||
| Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 | Q29619644 | ||
| Sphingosine-1-phosphate: an enigmatic signalling lipid | Q29620563 | ||
| Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci | Q30417517 | ||
| Glutathione deficiency is associated with impaired survival in HIV disease | Q30454442 | ||
| Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial | Q33338797 | ||
| Methotrexate Promotes Platelet Apoptosis via JNK-Mediated Mitochondrial Damage: Alleviation by N-Acetylcysteine and N-Acetylcysteine Amide | Q33423690 | ||
| Expression and regulation of HIF-1alpha in macrophages under inflammatory conditions; significant reduction of VEGF by CaMKII inhibitor | Q33547668 | ||
| Enhancing CD8 T-cell memory by modulating fatty acid metabolism | Q33577204 | ||
| Persistent mitochondrial hyperpolarization, increased reactive oxygen intermediate production, and cytoplasmic alkalinization characterize altered IL-10 signaling in patients with systemic lupus erythematosus | Q33608533 | ||
| Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus | Q33664831 | ||
| Tuberous sclerosis and fulminant lupus in a young woman. | Q33664866 | ||
| Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus | Q33664993 | ||
| Oxidative stress in the pathology and treatment of systemic lupus erythematosus | Q33715508 | ||
| HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE. | Q33717763 | ||
| Estradiol promotes pentose phosphate pathway addiction and cell survival via reactivation of Akt in mTORC1 hyperactive cells | Q33720145 | ||
| Increased mitochondrial electron transport chain activity at complex I is regulated by N-acetylcysteine in lymphocytes of patients with systemic lupus erythematosus | Q33722895 | ||
| Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study | Q33737181 | ||
| Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial | Q33806121 | ||
| Reactive oxygen species in tumor necrosis factor-alpha-activated primary human keratinocytes: implications for psoriasis and inflammatory skin disease | Q33915587 | ||
| FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction | Q34047681 | ||
| Oxidative stress, T cell DNA methylation, and lupus | Q34077487 | ||
| mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus? | Q34107250 | ||
| mTOR regulates the invasive properties of synovial fibroblasts in rheumatoid arthritis | Q34112686 | ||
| Metformin attenuates experimental autoimmune arthritis through reciprocal regulation of Th17/Treg balance and osteoclastogenesis | Q34151605 | ||
| Novel heterozygous mutations in TALDO1 gene causing transaldolase deficiency and early infantile liver failure | Q34152559 | ||
| The S1P(1)-mTOR axis directs the reciprocal differentiation of T(H)1 and T(reg) cells. | Q34217756 | ||
| Identification of a lipid peroxidation product as the source of oxidation-specific epitopes recognized by anti-DNA autoantibodies. | Q34232022 | ||
| mTOR pathway is activated by PKA in adrenocortical cells and participates in vivo to apoptosis resistance in primary pigmented nodular adrenocortical disease (PPNAD). | Q34285768 | ||
| Regulation of mTORC1 and its impact on gene expression at a glance | Q34342717 | ||
| Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus | Q34361763 | ||
| Mechanical activation of mammalian target of rapamycin pathway is required for cartilage development | Q34365539 | ||
| Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus | Q34412837 | ||
| FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle | Q34463962 | ||
| Suppression of autoimmunity and organ pathology in lupus-prone mice upon inhibition of calcium/calmodulin-dependent protein kinase type IV. | Q34538178 | ||
| Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis | Q34624835 | ||
| Rapamycin-sensitive signals control TCR/CD28-driven Ifng, Il4 and Foxp3 transcription and promoter region methylation | Q34628368 | ||
| ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase. | Q34728044 | ||
| Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis | Q34778631 | ||
| The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. | Q34801853 | ||
| Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies | Q34889152 | ||
| Etiopathogenesis of osteoarthritis | Q34896401 | ||
| Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study | Q34923104 | ||
| mTOR inhibition rescues osteopenia in mice with systemic sclerosis | Q34924612 | ||
| Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation | Q34939946 | ||
| Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability | Q34979483 | ||
| Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses. | Q34979730 | ||
| Regulation of mammalian translation factors by nutrients | Q34992453 | ||
| Circulating TFH subset distribution is strongly affected in lupus patients with an active disease | Q34999539 | ||
| Oxidative stress, inflammation and carcinogenesis are controlled through the pentose phosphate pathway by transaldolase | Q35048149 | ||
| T-cell metabolism in autoimmune disease | Q35071556 | ||
| Abnormalities of T cell signaling in systemic lupus erythematosus | Q35092855 | ||
| An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. | Q35097239 | ||
| KN-93, an inhibitor of calcium/calmodulin-dependent protein kinase IV, promotes generation and function of Foxp3⁺ regulatory T cells in MRL/lpr mice. | Q35124586 | ||
| Redox regulates mammalian target of rapamycin complex 1 (mTORC1) activity by modulating the TSC1/TSC2-Rheb GTPase pathway | Q35213308 | ||
| The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile. | Q35216878 | ||
| Autophagy activation and protection from mitochondrial dysfunction in human chondrocytes. | Q35236233 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sirolimus | Q32089 |
| P304 | page(s) | 169-182 | |
| P577 | publication date | 2015-12-24 | |
| P1433 | published in | Nature Reviews Rheumatology | Q2107227 |
| P1476 | title | Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases | |
| P478 | volume | 12 |
| Q55163735 | Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus. |
| Q37649687 | Activation of the Mechanistic Target of Rapamycin in SLE: Explosion of Evidence in the Last Five Years |
| Q64913678 | Active Tonic mTORC1 Signals Shape Baseline Translation in Naive T Cells. |
| Q33774045 | Activity-independent targeting of mTOR to lysosomes in primary osteoclasts |
| Q92314304 | An Overview of the Intrinsic Role of Citrullination in Autoimmune Disorders |
| Q47665041 | Autoimmune potential of perchloroethylene: Role of lipid-derived aldehydes |
| Q55260294 | Axial Spondyloarthritis and Autosomal Dominant Polycystic Kidney Disease in Two Siblings: A Rare Cooccurrence. |
| Q90009309 | B cells control lupus autoimmunity by inhibiting Th17 and promoting Th22 cells |
| Q61796261 | Baicalin ameliorates lupus autoimmunity by inhibiting differentiation of Tfh cells and inducing expansion of Tfr cells |
| Q92600821 | Biomaterials to Mimic and Heal Connective Tissues |
| Q55421717 | Biotin Deficiency Induces Th1- and Th17-Mediated Proinflammatory Responses in Human CD4+ T Lymphocytes via Activation of the mTOR Signaling Pathway. |
| Q47574467 | Blockade of Treg Cell Differentiation and Function by the Interleukin-21-Mechanistic Target of Rapamycin Axis Via Suppression of Autophagy in Patients With Systemic Lupus Erythematosus |
| Q104559093 | COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease |
| Q61798742 | Clinical Experience of Sirolimus Regarding Efficacy and Safety in Systemic Lupus Erythematosus |
| Q99711704 | Clinical efficacy and safety of sirolimus in systemic lupus erythematosus: a real-world study and meta-analysis |
| Q42371922 | Context-Specific Function of S6K2 in Th Cell Differentiation. |
| Q47892707 | Controlled Release of Second Generation mTOR Inhibitors to Restrain Inflammation in Primary Immune Cells |
| Q52447428 | Differential ability of proinflammatory and anti-inflammatory macrophages to perform macropinocytosis. |
| Q55036970 | Effect of Chronic Oxidative Stress on Neuroinflammatory Response Mediated by CD4+T Cells in Neurodegenerative Diseases. |
| Q38909420 | Empowering Regulatory T Cells in Autoimmunity |
| Q37597272 | Everolimus is better than rapamycin in attenuating neuroinflammation in kainic acid-induced seizures |
| Q92929300 | Exogenous Hydrogen Sulfide Regulates the Growth of Human Thyroid Carcinoma Cells |
| Q49257611 | Exploiting immune cell metabolic machinery for functional HIV cure and the prevention of inflammaging. |
| Q92857748 | Fatigue, Sleep, and Autoimmune and Related Disorders |
| Q39343327 | Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. |
| Q39223057 | Fine tuning of immunometabolism for the treatment of rheumatic diseases |
| Q90588415 | Future prospects for CD8+ regulatory T cells in immune tolerance |
| Q55514451 | Genetic contributions to lupus nephritis in a multi-ethnic cohort of systemic lupus erythematous patients. |
| Q47683360 | Heterotopic ossification and the elucidation of pathologic differentiation |
| Q38973345 | Immune Cell Metabolism in Systemic Lupus Erythematosus |
| Q39209693 | Immunometabolism in early and late stages of rheumatoid arthritis. |
| Q39209701 | Immunometabolism in systemic lupus erythematosus |
| Q60044009 | Immunosuppressive therapy influences the accelerated age-dependent T-helper cell differentiation in systemic lupus erythematosus remission patients |
| Q61797060 | Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sjögren's syndrome: mTOR inhibition as a novel therapeutic strategy to halt immunopathology? |
| Q98735567 | Intestinal Dysbiosis and Tryptophan Metabolism in Autoimmunity |
| Q54504436 | Mediators and Patterns of Muscle Loss in Chronic Systemic Inflammation. |
| Q94502517 | Metabolic Checkpoints in Rheumatoid Arthritis |
| Q37612885 | Metabolic Factors that Contribute to Lupus Pathogenesis |
| Q92072375 | Metabolic Pathways Involved in Regulatory T Cell Functionality |
| Q50579001 | Metabolic Reprogramming Commits Differentiation of Human CD27+IgD+ B Cells to Plasmablasts or CD27-IgD- Cells. |
| Q93272085 | Metabolic Targets for Treatment of Autoimmune Diseases |
| Q39390654 | Metabolic abnormalities and oxidative stress in lupus |
| Q38786619 | Metabolic control of arthritis: Switch pathways to treat |
| Q92569677 | Metabolic regulation of TH17 cells |
| Q38439401 | Metabolism of murine TH 17 cells: Impact on cell fate and function |
| Q92522644 | Metformin improves salivary gland inflammation and hypofunction in murine Sjögren's syndrome |
| Q37372436 | Mitochondrial Dysfunction in the Liver and Antiphospholipid Antibody Production Precede Disease Onset and Respond to Rapamycin in Lupus-Prone Mice |
| Q92508780 | Molecular and Cellular Bases of Immunosenescence, Inflammation, and Cardiovascular Complications Mimicking "Inflammaging" in Patients with Systemic Lupus Erythematosus |
| Q50420436 | Nanoparticles for the Induction of Antigen-Specific Immunological Tolerance. |
| Q28071300 | Oxidative Stress and Treg and Th17 Dysfunction in Systemic Lupus Erythematosus |
| Q54979940 | PEST-containing nuclear protein mediates the proliferation, migration, and invasion of human neuroblastoma cells through MAPK and PI3K/AKT/mTOR signaling pathways. |
| Q92670754 | Pathogenesis and treatment of autoimmune rheumatic diseases |
| Q39379152 | Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective |
| Q90456884 | RNAi Silencing of HIF-1α Ameliorates Lupus Development in MRL/lpr Mice |
| Q41182614 | Rapamycin Maintains the Chondrocytic Phenotype and Interferes with Inflammatory Cytokine Induced Processes. |
| Q38669113 | Recent advances in nanomedicines for the treatment of rheumatoid arthritis |
| Q57471979 | Regulatory T cells in the treatment of disease |
| Q47133379 | Review: Metabolic Control of Immune System Activation in Rheumatic Diseases |
| Q50069715 | SLE-Associated Defects Promote Altered T Cell Function. |
| Q91326688 | Sirolimus for systemic lupus erythematosus - Authors' reply |
| Q52650139 | Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial. |
| Q90614042 | Splicing factor SRSF1 controls T cell homeostasis and its decreased levels are linked to lymphopenia in systemic lupus erythematosus |
| Q93122187 | Splicing factor SRSF1 controls T cell hyperactivity and systemic autoimmunity |
| Q52890839 | Systemic lupus erythematosus in 2015: Cellular and metabolic requirements of effector T cells. |
| Q39014159 | Systemic lupus erythematosus in the light of the regulatory effects of galectin-1 on T-cell function |
| Q37727495 | T Cells in Osteoarthritis: Alterations and Beyond |
| Q92712487 | T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy |
| Q39175811 | T cells and autoimmune kidney disease. |
| Q91863929 | Targeting HMGB1 by ethyl pyruvate ameliorates systemic lupus erythematosus and reverses the senescent phenotype of bone marrow-mesenchymal stem cells |
| Q60958597 | The Impact of Protein Acetylation/Deacetylation on Systemic Lupus Erythematosus |
| Q50531937 | The Potential Role of Trained Immunity in Autoimmune and Autoinflammatory Disorders. |
| Q41423362 | The mTORC1-4E-BP-eIF4E axis controls de novo Bcl6 protein synthesis in T cells and systemic autoimmunity. |
| Q57491938 | mTOR Regulation of Glycolytic Metabolism in T Cells |
| Q55238879 | mTOR Senses Environmental Cues to Shape the Fibroblast-like Synoviocyte Response to Inflammation. |
| Q48037675 | mTOR Signaling Regulates Protective Activity of Transferred CD4+Foxp3+ T Cells in Repair of Acute Kidney Injury |
| Q38782266 | mTOR drives cerebral blood flow and memory deficits in LDLR(-/-) mice modeling atherosclerosis and vascular cognitive impairment |
| Q37395797 | mTOR has distinct functions in generating versus sustaining humoral immunity. |
| Q96952227 | mTOR sustains inflammatory response in celiac disease |
| Q89977007 | mTOR-Related Cell-Clearing Systems in Epileptic Seizures, an Update |
Search more.